Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocystis carinii Pneumonia in AIDS

Research output: Contribution to journalArticle

353 Citations (Scopus)

Abstract

The safety and efficacy of sulfamethoxazole and trimethoprim in the prevention of Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome (AIDS) were evaluated. Sixty patients with a new diagnosis of Kaposi’s sarcoma and no history of opportunistic infections were randomly assigned to receive 800 mg of sulfamethoxazole and 160 mg of trimethoprim twice per day or no therapy. None of the 30 patients receiving sulfamethoxazole and trimethoprim developed P carinii pneumonia. Sixteen of the 30 patients receiving no suppressive therapy developed P carinii pneumonia. Development of P carinii pneumonia was associated with the stage of Kaposi’s sarcoma, B subtype disease, and the presence of 0.20 × 109/L (200/mm3) or fewer CD4 cells at study entry. The proportion of patients surviving and the mean length of survival were significantly greater in the treatment group compared with the control group. Adverse reactions occurred in 15 patients (50%).

Original languageEnglish (US)
Pages (from-to)1185-1189
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume259
Issue number8
DOIs
StatePublished - Feb 26 1988

Fingerprint

Pneumocystis Pneumonia
Sulfamethoxazole Drug Combination Trimethoprim
Chemoprevention
Acquired Immunodeficiency Syndrome
Safety
Pneumonia
Kaposi's Sarcoma
Sulfamethoxazole
Trimethoprim
Opportunistic Infections
Therapeutics
Control Groups
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{cfd834f0e46d44a3ba1d47aa2ea7f443,
title = "Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocystis carinii Pneumonia in AIDS",
abstract = "The safety and efficacy of sulfamethoxazole and trimethoprim in the prevention of Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome (AIDS) were evaluated. Sixty patients with a new diagnosis of Kaposi’s sarcoma and no history of opportunistic infections were randomly assigned to receive 800 mg of sulfamethoxazole and 160 mg of trimethoprim twice per day or no therapy. None of the 30 patients receiving sulfamethoxazole and trimethoprim developed P carinii pneumonia. Sixteen of the 30 patients receiving no suppressive therapy developed P carinii pneumonia. Development of P carinii pneumonia was associated with the stage of Kaposi’s sarcoma, B subtype disease, and the presence of 0.20 × 109/L (200/mm3) or fewer CD4 cells at study entry. The proportion of patients surviving and the mean length of survival were significantly greater in the treatment group compared with the control group. Adverse reactions occurred in 15 patients (50{\%}).",
author = "Fischl, {Margaret A} and Gordon Dickinson and Lawrence Vole",
year = "1988",
month = "2",
day = "26",
doi = "10.1001/jama.259.8.1185",
language = "English (US)",
volume = "259",
pages = "1185--1189",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocystis carinii Pneumonia in AIDS

AU - Fischl, Margaret A

AU - Dickinson, Gordon

AU - Vole, Lawrence

PY - 1988/2/26

Y1 - 1988/2/26

N2 - The safety and efficacy of sulfamethoxazole and trimethoprim in the prevention of Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome (AIDS) were evaluated. Sixty patients with a new diagnosis of Kaposi’s sarcoma and no history of opportunistic infections were randomly assigned to receive 800 mg of sulfamethoxazole and 160 mg of trimethoprim twice per day or no therapy. None of the 30 patients receiving sulfamethoxazole and trimethoprim developed P carinii pneumonia. Sixteen of the 30 patients receiving no suppressive therapy developed P carinii pneumonia. Development of P carinii pneumonia was associated with the stage of Kaposi’s sarcoma, B subtype disease, and the presence of 0.20 × 109/L (200/mm3) or fewer CD4 cells at study entry. The proportion of patients surviving and the mean length of survival were significantly greater in the treatment group compared with the control group. Adverse reactions occurred in 15 patients (50%).

AB - The safety and efficacy of sulfamethoxazole and trimethoprim in the prevention of Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome (AIDS) were evaluated. Sixty patients with a new diagnosis of Kaposi’s sarcoma and no history of opportunistic infections were randomly assigned to receive 800 mg of sulfamethoxazole and 160 mg of trimethoprim twice per day or no therapy. None of the 30 patients receiving sulfamethoxazole and trimethoprim developed P carinii pneumonia. Sixteen of the 30 patients receiving no suppressive therapy developed P carinii pneumonia. Development of P carinii pneumonia was associated with the stage of Kaposi’s sarcoma, B subtype disease, and the presence of 0.20 × 109/L (200/mm3) or fewer CD4 cells at study entry. The proportion of patients surviving and the mean length of survival were significantly greater in the treatment group compared with the control group. Adverse reactions occurred in 15 patients (50%).

UR - http://www.scopus.com/inward/record.url?scp=85047694245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047694245&partnerID=8YFLogxK

U2 - 10.1001/jama.259.8.1185

DO - 10.1001/jama.259.8.1185

M3 - Article

C2 - 3257532

AN - SCOPUS:85047694245

VL - 259

SP - 1185

EP - 1189

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 8

ER -